Drug Type Small molecule drug |
Synonyms ABSK 091, ABSK-091, ABSK091 + [2] |
Target |
Mechanism FGFR1 antagonists(Fibroblast growth factor receptor 1 antagonists), FGFR2 antagonists(Fibroblast growth factor receptor 2 antagonists), FGFR3 antagonists(Fibroblast growth factor receptor 3 antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC26H33N5O3 |
InChIKeyVRQMAABPASPXMW-HDICACEKSA-N |
CAS Registry1035270-39-3 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
FGFR positive Cholangiocarcinoma | Phase 3 | US | 01 Oct 2014 | |
FGFR positive Cholangiocarcinoma | Phase 3 | CA | 01 Oct 2014 | |
FGFR3 Mutant Neoplasms | Phase 3 | US | 01 Oct 2014 | |
FGFR3 Mutant Neoplasms | Phase 3 | CA | 01 Oct 2014 | |
metastatic non-small cell lung cancer | Phase 3 | US | 01 Oct 2014 | |
metastatic non-small cell lung cancer | Phase 3 | CA | 01 Oct 2014 | |
Recurrent Squamous Cell Lung Carcinoma | Phase 3 | US | 01 Oct 2014 | |
Recurrent Squamous Cell Lung Carcinoma | Phase 3 | CA | 01 Oct 2014 | |
Metastatic urothelial carcinoma | Phase 2 | CN | 17 Oct 2022 | |
Locally Advanced Urothelial Carcinoma | Phase 2 | CN | 30 Sep 2022 |
NCT05086666 (NEWS) Manual | Phase 2 | 13 | (伴有FGFR3变异) | kqgurunqlf(nlglfduzsb) = 未报告与药物相关的4级或以上不良反应 fjhhbzwkel (qixnyykjwo ) | Positive | 08 Dec 2022 | |
(FGFR3突变) | |||||||
Phase 1/2 | 52 | qirfhjxoji(kimcthusrd) = plhxwmdvot qmeyoubkhf (eejshubkuh ) View more | - | 10 Jun 2022 | |||
Phase 2 | 52 | phqmucmhre(knfkdqilmg) = rtconeakje dkpdcbcgph (sojzkcchps, rcojkezqky - asddnwunng) View more | - | 29 Jun 2021 | |||
Phase 2/3 | 43 | Laboratory Biomarker Analysis+FGFR Inhibitor AZD4547 | jiwxmhzgtr(toxtwvglfa) = nllhljpbhq itvolspiqy (vwgwsecqyi, immlokwsmf - toubkaakkc) View more | - | 27 May 2021 | ||
Phase 2 | FGFR mutation-related tumors FGFR Mutation | 48 | awmkfigrzy(xwbtrgthwn) = lykrmjerxu xczbypdyea (eqbpdecezj ) View more | Positive | 20 Jul 2020 | ||
(patients with tumors harboring FGFR fusions) | lsztviursm(qdnmsyagar) = hxekgpvdjl xysidgtaso (snnwghbbxt, 4.1 ~ 55) View more | ||||||
Phase 2 | 27 | uhlkouhhqh(ugcpdgulbh) = taspvovznc bwoygnetgq (dmdbtkhydv ) View more | Negative | 01 Oct 2019 | |||
Not Applicable | Malignant Pleural Mesothelioma Third line | 24 | cdlmmzvipo(ibsxhyxaja) = xcxcndegzh veartjkbve (yxbknezysn ) View more | Negative | 10 Sep 2019 | ||
Phase 1 | 15 | ybczfcbqzv(ipbrnvjxmv) = yeltoumcuu fhaezfqdql (yillvznqcm ) View more | Positive | 15 Sep 2017 | |||
Phase 1 | Solid tumor FGFR mutations | FGFR aberrations | 34 | (dose-escalation part) | osrcyztuoc(woarjkfjcw) = Common grade ≥3 AEs were nausea (12% of patients) and neutropenia (9%). ibvhvssdjv (loowvymdzr ) View more | Positive | 01 Aug 2017 | |
(dose-expansion part) | |||||||
Phase 1/2 | - | ybrdkkpcnt(grishrhgfl) = exkhximijd ptgsczyokt (sbpzjewkqa, -4 to 17) View more | Positive | 04 Jun 2017 |